Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 3—March 2009


Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries

David S. FedsonComments to Author 
Author affiliation: University of Virginia, Charlottesville, Virginia, USA (retired)

Main Article

Table 2

Recent studies of patients with pneumonia treated with statins*

Investigator (reference) Study design and population Principal outcome Adjusted odds ratio (95% CI) or % reduction (p value)
van der Garde et al. (17)
Case–control diabetes patients, 4,719/15,322
Pneumonia hospitalization
0.50 (0.28-0.89)
Schlienger et al. (18) Case–control, 1,227/4,734 Pneumonia hospitalization 0.63 (0.46–0.88)

30-day pneumonia mortality rate
0.47 (0.25–0.88)
Mortensen et al. (19)
Retrospective cohort, 1,566/7,086
30-day pneumonia mortality rate
0.54 (0.42–0.70)
Chalmers et al. (20)
Prospective cohort, 257/750
30-day pneumonia mortality rate
0.46 (0.25– 0.85)
Thomsen et al. (21)
Retrospective cohort, 1,372/28,528
30-day pneumonia mortality rate
0.69 (0.58–0.82)
Majumdar et al. (22) Prospective cohort, 325/3,090 Hospital mortality rate and ICU admission (adjusted for administrative data) 0.88 (0.63–1.22)

Hospital mortality rate and ICU admission (adjusted for age, propensity score, clinical data, and functional status)
1.10 (0.76–1.60)
Choi et al. (23) Randomized controlled trial, ICU treatment; 33 with atorvastatin and 34 controls ICU mortality rate 45.4 (0.08)
Hospital mortality rate 51.2 (0.026)

*Except for the inpatient randomized controlled trial of Choi et al (23), recent treatment in the observational studies was defined as a statin prescription within a period of 30 days (18) to 90 days before hospitalization for pneumonia. CI, confidence interval; ICU, intensive care unit.

Main Article